Merz, Inc. completed the acquisition of ONMEL (itraconazole), an azole antifungal indicated for the oral treatment of onychomycosis of the toenail caused by Trichophyton rubrumor T. Mentagrophytes in non-immunocompromised patients. According to the company, ONMEL is the only FDA-approved oral treatment dosed in a once-a-day 200mg single tablet of itraconazole. ONMEL uses Meltrex (melt extrusion) Technology.